Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Health Behavior Change During COVID-19 Pandemic

8. august 2021 oppdatert av: University of Social Sciences and Humanities, Warsaw

Health Behavior Change During COVID-19 Pandemic: the Focus on Handwashing

This study aims at investigating handwashing behavior during COVID-19 pandemic. It was hypothesized that social-cognitive and emotional predictors as well as COVID-19 morbidity and mortality rates within the country would be associated with handwashing behavior in the general population of adults in 14 countries.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This observational study aims at testing the adherence to handwashing guidelines (the World Health Organization, WHO, 2020) at two measurement points, spanning 1 month. Adults from the general population in 14 countries (Poland, Australia, Canada, China, France, Gambia, Germany, Israel, Italy, Malaysia, Portugal, Romania, Singapore, Switzerland) will provide self-report data on handwashing behavior and its social-cognitive predictors (perceived effectiveness of handwashing, risk perception, outcome expectancy, self-efficacy, intention, planning, and action control), anxiety, as well as COVID-19 morbidity and mortality rates within the country.

Studietype

Observasjonsmessig

Registrering (Faktiske)

6079

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Australia
      • Melbourne, Australia
        • The University of Melbourne
  • Canada
      • Fredericton, Canada
        • University of New Brunswick
  • Frankrike
      • Bordeaux, Frankrike
        • University of Bordeaux
  • Gambia
      • Fajara, Gambia
        • London School of Hygiene and Tropical Medicine (in collaboration with MRC Unit The Gambia at LSHTM)
  • Israel
      • Ramat Gan, Israel
        • Bar-Ilan University
  • Italia
      • Padova, Italia
        • University of Padova
  • Kina
      • Beijing, Kina
        • Peking University
  • Malaysia
      • Serdang, Malaysia
        • Perdana University
  • Polen
    • Lower Silezia
      • Wroclaw, Lower Silezia, Polen, 53-328
        • SWPS University of Social Sciences and Humanities
  • Portugal
      • Lisbon, Portugal
        • University of Lisbon
  • Romania
      • Cluj-Napoca, Romania
        • Babes-Bolyai Unversity
  • Singapore
      • Singapore, Singapore
        • Nanyang Technological University
  • Sveits
      • Zürich, Sveits
        • University of Zurich
  • Tyskland
      • Berlin, Tyskland
        • Freie Universität Berlin

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adults in 14 countries are recruited using the snowballing method. Data are collected using an online platform (software: Qualtricts).

Beskrivelse

Inclusion Criteria:

  • adults (from general population) who provided informed consent to participate

Exclusion Criteria:

  • younger than <18 years old

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Poland
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Australia
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Canada
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
China
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
France
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Gambia
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Germany
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Israel
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Italy
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Malaysia
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Portugal
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Romania
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Singapore
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Switzerland
Adults, general population, N = 400
Annen: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Handwashing adherence
Tidsramme: 1 month
The 12-item self-report measure of adherence to handwashing guidelines across situations (e.g., after visiting public spaces, after touching garbage, etc.) based on the guidelines issued by the World Health Organization and the Centers for Disease Control and Prevention. The responses are provided on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree). Higher scores indicate better outcomes (the higher level of adherence to handwashing guidelines).
1 month
Frequency of handwashing
Tidsramme: 1 month
The 1-item self-report measure of the frequency of handwashing (for at least 20 seconds, all surfaces of the hands) daily. The responses are provided on a 4-point scale, ranging from 1 (less than once) to 5 (more than 10 times). Higher scores indicate better outcomes (the higher frequency of handwashing).
1 month

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Self-efficacy
Tidsramme: 1 month
4 self-efficacy questionnaire items; mean item score ranging from 1 to 4, higher scores indicate stronger self-efficacy
1 month
Risk perception
Tidsramme: 1 month
3 questionnaire items to assess risk perception; mean item score ranging from 1 to 5, higher scores indicate higher risk perception
1 month
Outcome expectancy
Tidsramme: 1 month
4 items assessing positive (1 item) and negative (1 items) outcome expectancies; mean item scores ranging from 1 to 4, higher scores indicate more positive outcome expectancies
1 month
Intention
Tidsramme: 1 month
2 questionnaire items assessing intention to adhere to handwashing recommendations; mean item scores ranging from 1 to 4, higher scores indicate stronger intention to wash hands (for at least 20 seconds, all surfaces of the hands)
1 month
Planning
Tidsramme: 1 month
2 questionnaire items assessing action planning (1 item) and coping planning (1 item); mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported planning
1 month
Action control
Tidsramme: 1 month
3 questionnaire items assessing a facet of action control, namely self-monitoring; mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported monitoring of handwashing behavior
1 month
Perceived effectiveness of hand hygiene
Tidsramme: 1 month
1 questionnaire item assessing perceptions of handwashing as an effective means of preventing coronavirus SARS-CoV-2 infection; item scores ranging from 1 to 4, higher scores indicate a higher level of perceived effectiveness of hand hygiene
1 month
Anxiety
Tidsramme: 1 month
7-item self-report scale (Generalized Anxiety Disorder, GAD-7) scale to assess anxiety symptoms; mean item scores ranging from 1 to 4, higher scores indicate a higher level of generalized anxiety
1 month
Country-level COVID-19 morbidity and mortality rates
Tidsramme: 60 days
The daily cumulative numbers for COVID-19 morbidity and mortality in the study countries. Published daily as the Situation Report by World Health Organization, starting on 21 January 2020. Higher numbers indicate the higher cumulative COVID-19 morbidity and mortality rates in the country.
60 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

University of Social Sciences and Humanities, Warsaw

Etterforskere

  • Hovedetterforsker: Aleksandra Luszczynska, PhD, SWPS University of Social Sciences and Humanities

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. mars 2020

Primær fullføring (Faktiske)

24. september 2020

Studiet fullført (Faktiske)

24. september 2020

Datoer for studieregistrering

Først innsendt

28. april 2020

Først innsendt som oppfylte QC-kriteriene

28. april 2020

Først lagt ut (Faktiske)

29. april 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. august 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. august 2021

Sist bekreftet

1. august 2020

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 3228-1BPSYPSBEH-30

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

The lead researchers in 14 countries will have full access to data collected across the countries.

In line with the Consortium Agreement (v2, 16th Jul 2020) data will be openly available under following conditions:

De-identified individual participant data that underline the results reported in publications; individual-level aggregated data (e.g., sum scores for scales) used for main analyses in respective publications; available following the publication, no end date of availability; available for analyses that are conducted to achieve aims in the approved proposal.

Due to local regulations, there are exceptions in terms of data sharing rules (stated above):

  • AUSTRALIA: Data from Australia will be available for 5 years after collection.
  • GERMANY, SWITZERLAND: Instead of individual-level sum scores, variance-covariance matrices will be shared.
  • MALAYSIA: Data will not be shared.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Helseatferd

Kliniske studier på No intervention

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Kuwait

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere